Opportunities for Canada to Improve Global Access to Medicines

This report explores a number of drug development and delivery models for the Canadian government to consider implementing as it looks to improve access to essential medicines both domestically and internationally.The Office ofInternational Affairs for the Health Portfolio (OIA-HP) commissioned the research of four market-level case studies, which focus on innovative financing and collaborative initiatives, and one patient-level case study, which considers international legislation as a model to improve Canada’s purchasing power. The Innovative Medicines Initiative (IMI), the International Finance Facility for Immunization (IFFIm), Open Source Drug Discovery (OSDD), Drugs for Neglected Diseases Initiative (DNDi), and Australia’s Pharmaceutical Benefits Scheme (PBS) were specifically selected based on their relevance to Canada’s strong pharmaceutical industry, commitment to R&D and global aid, and domestic health needs (report available here). 

By Wojciech Copija, Lauren Degabriele, Mahi Hosseini, Ashley Schram, and Liliane Tshiama Kalonji.

ghlc_-_oia-hp_appendix.pdf1.23 MB
global_health_law_clinic_oiahp_report_.pdf3.21 MB